export interface ArticleSection {
  heading: string;
  content: string;
  list?: string[];
}

export interface ArticleFAQ {
  question: string;
  answer: string;
}

export interface Article {
  slug: string;
  title: string;
  metaTitle: string;
  metaDescription: string;
  keywords: string[];
  publishedDate: string;
  modifiedDate: string;
  category: string;
  readTime: number; // minutes
  excerpt: string;
  sections: ArticleSection[];
  faqs: ArticleFAQ[];
  relatedProducts: string[];
  relatedSlugs: string[];
}

export const articles: Article[] = [
  {
    slug: "bpc-157-research-overview",
    title: "BPC-157 Research Overview: What Scientists Are Studying",
    metaTitle: "BPC-157 Research Overview: What Scientists Are Studying | Vertex Research Labs",
    metaDescription:
      "A research-focused overview of BPC-157 (Body Protection Compound 157), covering its amino acid structure, mechanism studies, preclinical research history, and published literature. Lab use only.",
    keywords: [
      "BPC-157 research",
      "BPC-157 studies",
      "BPC-157 mechanism",
      "BPC-157 peptide science",
      "body protection compound 157 research",
      "BPC-157 preclinical",
      "BPC-157 published research",
      "BPC-157 amino acid sequence",
    ],
    publishedDate: "2025-01-15",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "BPC-157 is a synthetic pentadecapeptide that has attracted significant attention in preclinical research. This overview summarizes its structural properties, receptor interactions studied in the literature, and the published research record.",
    sections: [
      {
        heading: "What Is BPC-157?",
        content:
          "BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein sequence found in human gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it has a molecular weight of approximately 1419.5 Da. BPC-157 does not occur naturally in isolation; it is a partial sequence isolated from the parent gastric protein BPC and is available only as a synthetic research reference material.",
      },
      {
        heading: "Structural Properties",
        content:
          "As a pentadecapeptide, BPC-157 contains multiple proline residues which confer conformational rigidity, contributing to its relative stability compared to many other peptide sequences. Its chemical formula is C₆₂H₉₈N₁₆O₂₂. In laboratory settings it is supplied as a lyophilized (freeze-dried) powder and requires reconstitution with an appropriate sterile diluent before use in in vitro or in vivo research protocols.",
        list: [
          "Length: 15 amino acids (pentadecapeptide)",
          "Molecular weight: ~1419.5 Da",
          "Formula: C₆₂H₉₈N₁₆O₂₂",
          "Standard supply form: lyophilized powder",
          "Typical research purity standard: ≥99% by HPLC",
        ],
      },
      {
        heading: "Preclinical Research History",
        content:
          "The majority of published BPC-157 research originates from the laboratory of Professor Predrag Sikiric at the University of Zagreb. Studies appearing in journals including Current Pharmaceutical Design, Journal of Applied Physiology, and Journal of Physiology-Paris have examined BPC-157's interactions with nitric oxide (NO) signaling pathways, growth factor receptor expression, and cytoskeletal dynamics in rodent models. These are preclinical animal studies and do not constitute evidence of safety or efficacy in humans.",
      },
      {
        heading: "Key Research Areas in the Published Literature",
        content:
          "Published preclinical investigations have explored several areas of BPC-157 biology. It is important to note that all cited research represents animal or cell-culture findings only and has not been validated in human clinical trials.",
        list: [
          "Nitric oxide (NO) pathway interactions in rodent models",
          "VEGFR2 and FAK receptor expression in cell culture",
          "Tendon-to-bone junction healing models in rats",
          "Gut motility and gastric mucosal models",
          "Cytoskeletal (actin/tubulin) effects in vitro",
        ],
      },
      {
        heading: "Research Purity Standards",
        content:
          "For reproducible laboratory research, BPC-157 reference material should meet a minimum purity threshold of ≥99% as verified by High-Performance Liquid Chromatography (HPLC). Each batch should be accompanied by a Certificate of Analysis (COA) confirming purity, molecular identity (typically via mass spectrometry), and batch traceability. At Vertex Research Labs, every BPC-157 shipment includes independent third-party COA documentation.",
      },
      {
        heading: "Important Research Disclaimer",
        content:
          "All BPC-157 reference materials supplied by Vertex Research Labs are intended strictly for in vitro laboratory research and analytical applications. This material is not approved by the FDA or any regulatory authority for human or veterinary use. Nothing in this article constitutes medical advice, and BPC-157 should not be used outside of an authorized research setting.",
      },
    ],
    faqs: [
      {
        question: "What does BPC stand for in BPC-157?",
        answer:
          "BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid partial sequence derived from the larger BPC protein found in human gastric juice.",
      },
      {
        question: "Is there published clinical trial data on BPC-157?",
        answer:
          "As of 2025, the vast majority of BPC-157 research is preclinical — conducted in cell culture or rodent models. Limited early-phase human studies have been reported but no large-scale randomized controlled trials have been completed or published.",
      },
      {
        question: "What purity should research-grade BPC-157 be?",
        answer:
          "The standard benchmark for research-grade BPC-157 is ≥99% purity as verified by HPLC, accompanied by a Certificate of Analysis confirming identity and batch documentation.",
      },
      {
        question: "Where can I find published BPC-157 research?",
        answer:
          "PubMed is the primary database for peer-reviewed BPC-157 publications. Searching 'BPC-157' or 'body protection compound 157' returns the majority of indexed studies, predominantly from the Sikiric research group at the University of Zagreb.",
      },
    ],
    relatedProducts: ["bpc-157", "tb-500", "wolverine-blend"],
    relatedSlugs: [
      "tb-500-thymosin-beta-4-research",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "ghk-cu-copper-peptide-guide",
    title: "GHK-Cu Copper Peptide: Laboratory Reference Guide",
    metaTitle: "GHK-Cu Copper Peptide: Laboratory Reference Guide | Vertex Research Labs",
    metaDescription:
      "Comprehensive laboratory reference guide for GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper). Covers structure, copper-binding chemistry, published research, and purity standards for lab use.",
    keywords: [
      "GHK-Cu research",
      "GHK-Cu copper peptide guide",
      "GHK-Cu mechanism",
      "glycyl histidyl lysine copper",
      "copper peptide research",
      "GHK-Cu gene expression research",
      "GHK-Cu antioxidant research",
      "copper binding tripeptide",
    ],
    publishedDate: "2025-01-22",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 6,
    excerpt:
      "GHK-Cu is a naturally occurring copper-binding tripeptide studied extensively in cell biology research. This guide covers its chemistry, copper coordination, published research landscape, and specifications for laboratory use.",
    sections: [
      {
        heading: "What Is GHK-Cu?",
        content:
          "GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a tripeptide-copper(II) complex that occurs naturally in human plasma, saliva, and urine. It was first isolated by Loren Pickart in 1973 and has since become one of the most studied naturally occurring peptides in biochemistry research. The free tripeptide (GHK) has high affinity for copper(II) ions, and the resulting complex (GHK-Cu) is the primary research form.",
      },
      {
        heading: "Copper Coordination Chemistry",
        content:
          "The copper(II) ion in GHK-Cu is coordinated by three nitrogen atoms from the peptide backbone: the N-terminal amine of glycine, the peptide nitrogen between glycine and histidine, and the imidazole nitrogen of histidine. This square-planar coordination geometry is characteristic of type-II copper complexes and is central to GHK-Cu's documented interactions with biological systems in research settings.",
        list: [
          "Metal: Copper(II) (Cu²⁺)",
          "Coordination: Square-planar, 3N donor atoms",
          "Affinity constant for Cu²⁺: ~10¹⁷ M⁻¹ (extremely high)",
          "Molecular weight (GHK): ~340.4 Da",
          "Molecular weight (GHK-Cu): ~403.9 Da",
        ],
      },
      {
        heading: "Published Research Landscape",
        content:
          "GHK-Cu is among the most published naturally occurring peptides in biochemistry. Research by Pickart and colleagues, appearing in International Journal of Molecular Sciences (2015) and Oxidative Medicine and Cellular Longevity (2018), has examined GHK-Cu's modulation of over 4,000 human genes in cell culture models. Additional published work has investigated its interactions with antioxidant enzymes, collagen synthesis pathways, and the ubiquitin-proteasome system in vitro.",
      },
      {
        heading: "Research Applications",
        content:
          "In laboratory settings, GHK-Cu is used as a reference material across several research disciplines. All applications listed represent in vitro or preclinical contexts only.",
        list: [
          "Gene expression modulation studies (microarray, RNA-seq)",
          "Copper-binding peptide chemistry and coordination studies",
          "Antioxidant pathway research (SOD, catalase interactions)",
          "Extracellular matrix and collagen synthesis models",
          "Wound-healing cell migration assays (in vitro scratch assays)",
        ],
      },
      {
        heading: "Purity and Quality Standards",
        content:
          "Research-grade GHK-Cu should meet ≥99% purity by HPLC analysis. Because it is a metal complex, identity confirmation should include both peptide sequence verification and copper content analysis. Vertex Research Labs provides independent third-party COA documentation with every GHK-Cu batch, confirming purity, identity, and copper coordination.",
      },
      {
        heading: "Disclaimer",
        content:
          "GHK-Cu reference materials from Vertex Research Labs are supplied exclusively for laboratory research and analytical purposes. This material is not intended for human or veterinary use. Nothing in this guide constitutes medical advice or a health claim.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between GHK and GHK-Cu?",
        answer:
          "GHK is the free tripeptide (Glycyl-L-Histidyl-L-Lysine). GHK-Cu is the copper(II) complex of GHK. The copper-complexed form is the primary subject of biological research as the copper coordination is central to its documented activities in cell culture studies.",
      },
      {
        question: "How many genes has GHK-Cu been studied in relation to?",
        answer:
          "Microarray and RNA-seq studies in cell culture have examined GHK-Cu's influence on over 4,000 human genes, according to publications by Pickart and colleagues. These are in vitro findings and do not represent clinical outcomes.",
      },
      {
        question: "Is GHK-Cu naturally occurring?",
        answer:
          "Yes. GHK-Cu occurs naturally in human plasma (at approximately 200 ng/mL in young adults, declining with age), as well as in saliva and urine. The synthetic research form is produced to provide consistent, high-purity reference material for laboratory studies.",
      },
      {
        question: "What form does research-grade GHK-Cu ship in?",
        answer:
          "GHK-Cu is supplied as a lyophilized powder in sealed research vials. It is available in 50mg and 100mg formats from Vertex Research Labs.",
      },
    ],
    relatedProducts: ["ghk-cu", "ghk-cu-100", "epithalon", "bpc-157"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "retatrutide-triple-agonist-research",
    title: "Retatrutide: The Triple Agonist Peptide Researchers Are Watching",
    metaTitle: "Retatrutide Research Overview: GLP-1/GIP/Glucagon Triple Agonist | Vertex Research Labs",
    metaDescription:
      "Research overview of Retatrutide (LY3437943), the GLP-1, GIP, and glucagon triple receptor agonist peptide. Covers structure, Phase 2 trial data, and comparisons with Semaglutide and Tirzepatide.",
    keywords: [
      "Retatrutide research",
      "Retatrutide LY3437943",
      "triple agonist peptide research",
      "GLP-1 GIP glucagon agonist",
      "Retatrutide vs Semaglutide",
      "Retatrutide vs Tirzepatide",
      "Retatrutide Phase 2 trial",
      "GLP-1 peptide research 2024 2025",
      "incretin peptide research",
      "trending peptide research",
    ],
    publishedDate: "2025-02-01",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 8,
    excerpt:
      "Retatrutide (LY3437943) is a synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. Phase 2 trial data published in the New England Journal of Medicine has made it one of the most discussed peptides in metabolic research. This overview covers its structure, receptor pharmacology, and published clinical data.",
    sections: [
      {
        heading: "What Is Retatrutide?",
        content:
          "Retatrutide (INN: retatrutide; Eli Lilly code: LY3437943) is a synthetic acylated peptide designed as a triple agonist at three key metabolic hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-receptor pharmacology distinguishes it structurally from all currently approved GLP-1 class drugs and makes it a significant research subject in metabolic science.",
      },
      {
        heading: "Receptor Pharmacology",
        content:
          "Understanding Retatrutide's receptor targets requires context on the incretin hormone system. GLP-1R and GIPR are both incretin receptors involved in insulin secretion regulation, while GCGR mediates glucagon signaling. Retatrutide's triple agonism creates a distinct pharmacological profile that researchers are using to study the interaction between these three receptor pathways in metabolic regulation.",
        list: [
          "GLP-1R (Glucagon-like Peptide-1 Receptor) — incretin signaling",
          "GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor) — incretin signaling",
          "GCGR (Glucagon Receptor) — counterregulatory hormone signaling",
        ],
      },
      {
        heading: "Phase 2 Clinical Trial Data",
        content:
          "In June 2023, the New England Journal of Medicine published Phase 2 trial results for Retatrutide (Jastreboff AM et al., DOI: 10.1056/NEJMoa2301972). The trial enrolled 338 participants with obesity and examined multiple dose levels over 48 weeks. The published data represents a clinical research finding and does not constitute a treatment claim. Retatrutide remains an investigational compound with no approved indication as of 2025.",
      },
      {
        heading: "Structural Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide",
        content:
          "For researchers studying GLP-1 class peptides, the structural and pharmacological distinctions between these compounds are important reference points.",
        list: [
          "Semaglutide (Ozempic/Wegovy): GLP-1R mono-agonist, C18 fatty diacid acylation, ~34 amino acids",
          "Tirzepatide (Mounjaro/Zepbound): GLP-1R/GIPR dual agonist, C20 fatty diacid acylation, 39 amino acids",
          "Retatrutide (LY3437943): GLP-1R/GIPR/GCGR triple agonist, C20 fatty diacid acylation, ~39 amino acids",
        ],
      },
      {
        heading: "Research Grade Retatrutide Specifications",
        content:
          "As an investigational peptide, research-grade Retatrutide requires rigorous purity verification. Vertex Research Labs supplies Retatrutide at ≥99% purity as independently verified by HPLC, with mass spectrometry identity confirmation and batch-specific COA documentation. It is available in 10mg vials for laboratory use.",
      },
      {
        heading: "Regulatory Status and Disclaimer",
        content:
          "Retatrutide is an investigational compound. As of 2025 it has not received FDA approval or approval from any other regulatory authority for any indication. All Retatrutide reference materials from Vertex Research Labs are supplied exclusively for laboratory research use. This overview is for scientific reference only and does not constitute medical advice or a health claim of any kind.",
      },
    ],
    faqs: [
      {
        question: "What makes Retatrutide different from Semaglutide?",
        answer:
          "Semaglutide is a GLP-1 receptor mono-agonist. Retatrutide targets three receptors simultaneously: GLP-1R, GIPR, and GCGR. This triple-agonism creates a distinct pharmacological profile that is the primary subject of current research interest.",
      },
      {
        question: "Is Retatrutide FDA-approved?",
        answer:
          "No. As of 2025, Retatrutide (LY3437943) is an investigational compound that has not received FDA approval for any indication. It is available only as a research reference material.",
      },
      {
        question: "Where was the Retatrutide Phase 2 trial published?",
        answer:
          "The Phase 2 trial data was published in the New England Journal of Medicine in June 2023 (Jastreboff AM et al., NEJM 2023;389:514-526, DOI: 10.1056/NEJMoa2301972).",
      },
      {
        question: "What purity is research-grade Retatrutide?",
        answer:
          "Research-grade Retatrutide from Vertex Research Labs is independently verified at ≥99% purity by HPLC with a batch-specific Certificate of Analysis.",
      },
      {
        question: "Can I compare Retatrutide to Tirzepatide in my research?",
        answer:
          "Yes — as distinct reference materials, both are available for comparative receptor pharmacology research. Tirzepatide (dual GLP-1R/GIPR agonist) and Retatrutide (triple GLP-1R/GIPR/GCGR agonist) represent useful structural and pharmacological comparators in incretin research.",
      },
    ],
    relatedProducts: ["retatrutide", "tesamorelin", "cjc-ipa-blend"],
    relatedSlugs: [
      "glp1-peptides-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "mots-c-mitochondrial-peptide-research",
    title: "MOTS-c: The Mitochondrial-Derived Peptide Redefining Longevity Research",
    metaTitle: "MOTS-c Research Overview: Mitochondrial-Derived Peptide | Vertex Research Labs",
    metaDescription:
      "Research overview of MOTS-c, a mitochondria-encoded peptide identified in Cell Metabolism (2015). Covers its mitochondrial origin, metabolic signaling research, and why it is trending in longevity science.",
    keywords: [
      "MOTS-c research",
      "mitochondrial derived peptide",
      "MOTS-c Cell Metabolism",
      "MOTS-c longevity research",
      "MOTS-c metabolic signaling",
      "mitokine research",
      "MOTS-c 12S rRNA",
      "MOTS-c preclinical",
      "trending longevity peptides 2025",
    ],
    publishedDate: "2025-02-10",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — an entirely new class of signaling molecule. Since its landmark identification in Cell Metabolism (2015), it has become one of the most actively studied peptides in longevity and metabolic research.",
    sections: [
      {
        heading: "What Is MOTS-c?",
        content:
          "MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by a short open reading frame within the 12S ribosomal RNA gene of the human mitochondrial genome. Its discovery, reported by Lee C et al. in Cell Metabolism (2015), established a new category of bioactive molecules: mitochondria-derived peptides (MDPs), also called mitokines. MOTS-c's sequence is MRWQEMGYIFYPRKLR.",
      },
      {
        heading: "A New Category: Mitochondria-Derived Peptides",
        content:
          "For decades, the mitochondrial genome was considered to encode only 13 proteins, 22 tRNAs, and 2 rRNAs — all components of the oxidative phosphorylation machinery. The discovery of MOTS-c and other short open reading frames within mitochondrial non-coding regions expanded this understanding fundamentally. MDPs are now recognized as a distinct class of signaling molecules that can translocate from mitochondria to the cytoplasm and nucleus, acting as retrograde signals between mitochondria and the rest of the cell.",
        list: [
          "Source: Mitochondrial 12S rRNA gene small open reading frame",
          "Length: 16 amino acids",
          "Sequence: MRWQEMGYIFYPRKLR",
          "Molecular weight: ~2174.5 Da",
          "Classification: Mitochondria-Derived Peptide (MDP) / Mitokine",
        ],
      },
      {
        heading: "Published Research: Metabolic Signaling",
        content:
          "The landmark 2015 Cell Metabolism paper (Lee C et al., DOI: 10.1016/j.cmet.2015.01.020) demonstrated that MOTS-c regulates the AMPK pathway and methionine metabolism via the folate cycle in cell and animal models. Subsequent research has examined MOTS-c's translocation to the nucleus under stress conditions and its interactions with ARE (Antioxidant Response Element) pathways. All findings to date are preclinical.",
      },
      {
        heading: "Why MOTS-c Is Trending in Longevity Research",
        content:
          "Several factors have converged to make MOTS-c one of the most-discussed peptides in longevity science circles as of 2024–2025.",
        list: [
          "Published in Cell Metabolism — one of the highest-impact journals in metabolic biology",
          "Novel mechanism: mitochondrial genome origin was unexpected",
          "AMPK pathway relevance connects it to established longevity research (metformin, rapamycin literature)",
          "Age-related decline in circulating MOTS-c levels observed in published studies",
          "Active ongoing research from multiple independent laboratories",
        ],
      },
      {
        heading: "Research Grade MOTS-c Specifications",
        content:
          "MOTS-c is available from Vertex Research Labs in 10mg and 40mg formats, both independently verified at ≥99% purity by HPLC with batch-specific COA documentation. Given its relatively short sequence and unique amino acid composition, identity confirmation via mass spectrometry is standard in our quality protocol.",
      },
      {
        heading: "Disclaimer",
        content:
          "MOTS-c reference materials from Vertex Research Labs are supplied exclusively for laboratory research use. No claims are made regarding any therapeutic, health, or clinical application. All research findings cited are preclinical and do not establish safety or efficacy in humans.",
      },
    ],
    faqs: [
      {
        question: "Where is MOTS-c encoded in the human genome?",
        answer:
          "MOTS-c is encoded within a short open reading frame in the 12S ribosomal RNA gene of the mitochondrial genome — not the nuclear genome. This makes it part of a newly discovered class called mitochondria-derived peptides (MDPs).",
      },
      {
        question: "What pathway does MOTS-c research focus on?",
        answer:
          "Published research has primarily focused on MOTS-c's interactions with the AMPK (AMP-activated protein kinase) pathway and methionine metabolism via the folate cycle, as identified in the 2015 Cell Metabolism paper by Lee et al.",
      },
      {
        question: "Is MOTS-c levels known to change with age?",
        answer:
          "Published studies have reported an age-related decline in circulating MOTS-c levels in both mice and humans, which has contributed to significant interest in this peptide within the longevity research community.",
      },
      {
        question: "What sizes is MOTS-c available in for research?",
        answer:
          "Vertex Research Labs offers MOTS-c in 10mg (standard) and 40mg (bulk) formats, both at ≥99% purity with independent COA documentation.",
      },
    ],
    relatedProducts: ["mots-c", "mots-c-40", "nad-plus", "epithalon"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "bpc-157-research-overview",
    ],
  },

  {
    slug: "epithalon-research-overview",
    title: "Epithalon (Epitalon) Research: A Tetrapeptide Overview",
    metaTitle: "Epithalon (Epitalon) Research Overview: Telomere & Longevity Science | Vertex Research Labs",
    metaDescription:
      "Research overview of Epithalon (Epitalon), the synthetic tetrapeptide Ala-Glu-Asp-Gly studied for telomerase interactions and pineal biology. Covers structure, published studies, and research specifications.",
    keywords: [
      "Epithalon research",
      "Epitalon research",
      "Epithalon telomere research",
      "Epithalon telomerase",
      "Epitalon peptide studies",
      "Epithalon Khavinson",
      "pineal peptide research",
      "tetrapeptide longevity research",
      "Epithalon preclinical",
      "anti-aging peptide research",
    ],
    publishedDate: "2025-02-18",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 6,
    excerpt:
      "Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a pineal gland extract. Research by Khavinson and colleagues has examined its interactions with telomerase activity and chromatin structure in cell culture models, making it one of the most discussed peptides in longevity research.",
    sections: [
      {
        heading: "What Is Epithalon?",
        content:
          "Epithalon (also spelled Epitalon; IUPAC: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It was derived from Epithalamin — a complex polypeptide extract of the bovine pineal gland that Khavinson's group studied beginning in the 1980s. Epithalon represents the isolated active tetrapeptide sequence from that larger extract and is the form used in modern research.",
        list: [
          "Sequence: Ala-Glu-Asp-Gly (AEDG)",
          "Molecular weight: ~390.35 Da",
          "Formula: C₁₄H₂₂N₄O₁₀",
          "Classification: Synthetic tetrapeptide / bioregulator",
          "Source of derivation: Epithalamin (bovine pineal extract)",
        ],
      },
      {
        heading: "Pineal Biology and Research Context",
        content:
          "The pineal gland is a small endocrine structure in the brain responsible for melatonin secretion and involved in circadian rhythm regulation. Khavinson's research group pursued the hypothesis that peptide bioregulators derived from various organs carry tissue-specific biological information. Epithalamin (and subsequently Epithalon) was their pineal-derived candidate. The majority of foundational Epithalon research originates from Khavinson's laboratory and affiliated Russian institutes.",
      },
      {
        heading: "Telomerase Research",
        content:
          "The area of Epithalon research attracting the most contemporary attention involves telomerase — the enzyme responsible for maintaining telomere length at chromosome ends. A study published in Bulletin of Experimental Biology and Medicine (Khavinson VK et al., 2003) reported telomerase activation in human somatic cells treated with Epithalon in vitro. This single finding has generated substantial interest, though independent replication in peer-reviewed literature remains limited. Researchers should interpret these findings in that context.",
      },
      {
        heading: "Chromatin and Gene Expression Research",
        content:
          "Beyond telomerase, Khavinson's group has published research examining Epithalon's interactions with chromatin structure and gene promoter regions. The proposed mechanism involves Epithalon binding to histone proteins and influencing chromatin accessibility, which would affect transcription factor binding. These findings are from cell culture and animal models only.",
      },
      {
        heading: "Why Epithalon Is Trending",
        content:
          "Several factors explain Epithalon's growing search volume and community interest in 2024–2025.",
        list: [
          "Telomere biology has become a high-profile research area following Nobel Prize recognition (Blackburn, Greider, Szostak, 2009)",
          "Longevity research is experiencing broader public and scientific interest",
          "Epithalon is one of the few peptides with published (though limited) telomerase interaction data",
          "It is relatively affordable as a research material compared to longer peptides",
          "Active discussion in longevity research communities online has driven search interest",
        ],
      },
      {
        heading: "Research Grade Specifications",
        content:
          "Epithalon is supplied by Vertex Research Labs in 10mg vials at ≥99% purity, independently verified by HPLC with batch-specific COA documentation. As a tetrapeptide, it is among the smaller peptide reference materials in our catalog, which contributes to its stability and relatively accessible price point.",
      },
      {
        heading: "Disclaimer",
        content:
          "Epithalon reference materials from Vertex Research Labs are supplied for laboratory research use only. Published research on Epithalon is predominantly from a single research group and has not been extensively independently replicated. No therapeutic, anti-aging, or health claims are made. This material is not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between Epithalon and Epithalamin?",
        answer:
          "Epithalamin is a complex polypeptide extract derived from bovine pineal glands. Epithalon (Ala-Glu-Asp-Gly) is the synthetic tetrapeptide identified as the active sequence within Epithalamin and is the standard form used in modern research.",
      },
      {
        question: "What is Epithalon's proposed interaction with telomerase?",
        answer:
          "A 2003 publication in Bulletin of Experimental Biology and Medicine by Khavinson et al. reported telomerase activation in human somatic cells treated with Epithalon in vitro. Independent replication of this finding in peer-reviewed literature remains limited.",
      },
      {
        question: "Is Epithalon the same as Epitalon?",
        answer:
          "Yes. Epithalon and Epitalon are two common spellings of the same tetrapeptide (Ala-Glu-Asp-Gly). The 'Epithalon' spelling is more common in English-language scientific literature.",
      },
      {
        question: "What purity is research-grade Epithalon?",
        answer:
          "Vertex Research Labs supplies Epithalon at ≥99% purity verified by HPLC, with a Certificate of Analysis included with every 10mg order.",
      },
    ],
    relatedProducts: ["epithalon", "ghk-cu", "mots-c", "dsip"],
    relatedSlugs: [
      "mots-c-mitochondrial-peptide-research",
      "ghk-cu-copper-peptide-guide",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "how-to-read-peptide-coa",
    title: "How to Read a Peptide Certificate of Analysis (COA)",
    metaTitle: "How to Read a Peptide Certificate of Analysis (COA) | Vertex Research Labs",
    metaDescription:
      "A complete guide to reading and verifying a peptide Certificate of Analysis. Covers HPLC purity data, mass spectrometry identity confirmation, batch numbers, and what to look for when evaluating a supplier.",
    keywords: [
      "how to read peptide COA",
      "peptide certificate of analysis",
      "HPLC peptide purity",
      "peptide COA explained",
      "peptide batch documentation",
      "verify peptide purity",
      "what is peptide COA",
      "research peptide quality verification",
      "mass spectrometry peptide identity",
      "peptide purity standards",
    ],
    publishedDate: "2025-03-01",
    modifiedDate: "2025-04-01",
    category: "Research Guide",
    readTime: 8,
    excerpt:
      "A Certificate of Analysis (COA) is the primary document for verifying peptide quality in research settings. This guide explains every section of a COA — from HPLC chromatograms to mass spec data — and what standards to hold suppliers to.",
    sections: [
      {
        heading: "What Is a Certificate of Analysis?",
        content:
          "A Certificate of Analysis (COA) is a quality assurance document issued for a specific batch of a compound. For research peptides, it provides analytical evidence that the material meets specified purity, identity, and quality standards. A COA is not a guarantee of safety or fitness for any particular use — it is a technical document confirming what the material is and how pure it is. Every serious research peptide supplier should provide a batch-specific COA, not a generic document reused across multiple lots.",
      },
      {
        heading: "Key Sections of a Peptide COA",
        content:
          "A complete peptide COA should contain the following elements. Absence of any of these sections is a red flag when evaluating a supplier.",
        list: [
          "Product name and catalog number",
          "Batch / lot number (must be batch-specific, not generic)",
          "Date of analysis",
          "Testing laboratory name (third-party independent is the gold standard)",
          "Purity result (% by HPLC, with chromatogram)",
          "Identity confirmation (mass spectrometry or amino acid analysis)",
          "Appearance description (e.g. white lyophilized powder)",
          "Storage conditions",
          "Analyst signature or laboratory stamp",
        ],
      },
      {
        heading: "Understanding HPLC Purity Data",
        content:
          "High-Performance Liquid Chromatography (HPLC) is the standard method for determining peptide purity. In a reverse-phase HPLC run, the peptide is separated from impurities based on hydrophobicity. The result is a chromatogram — a graph of UV absorbance (y-axis) versus time (x-axis). The main peak represents your peptide; smaller peaks represent impurities. Purity is calculated as the area of the main peak divided by the total area of all peaks, expressed as a percentage. Research-grade peptides should show ≥99% purity by this method, meaning the main peak accounts for at least 99% of total peak area.",
      },
      {
        heading: "Understanding Mass Spectrometry Identity Confirmation",
        content:
          "HPLC tells you how pure the material is but not definitively what it is. Mass spectrometry (MS) — typically ESI-MS or MALDI-TOF — provides molecular weight confirmation. The measured molecular ion (M+H)⁺ or (M+2H)²⁺ should match the theoretical molecular weight of the peptide within acceptable mass accuracy (typically ±0.1 Da for ESI-MS). For example, BPC-157 has a theoretical MW of 1419.5 Da; a COA showing [M+H]⁺ = 1420.5 is consistent. A mismatch indicates wrong identity or significant structural modification.",
      },
      {
        heading: "Third-Party vs. In-House Testing",
        content:
          "There is an important distinction between in-house COAs and third-party independent COAs. An in-house COA is generated by the supplier's own laboratory — there is a conflict of interest since the supplier is testing their own product. A third-party independent COA is generated by a laboratory with no commercial relationship to the supplier. Third-party COAs are the gold standard in research peptide quality verification. At Vertex Research Labs, all COAs are produced by independent analytical laboratories.",
      },
      {
        heading: "Batch-Specific vs. Generic COAs",
        content:
          "A batch-specific COA references a unique lot number that can be traced to a specific production run. A generic COA may show impressive purity numbers but applies to no specific batch — it cannot verify the material you actually received. Always check that the lot number on your COA matches the lot number on your vial label. If a supplier cannot provide a batch-specific COA, that is a significant quality concern.",
      },
      {
        heading: "Red Flags to Watch For",
        content:
          "When evaluating a peptide COA, these are common indicators of low-quality documentation.",
        list: [
          "No lot number or a generic lot number (e.g. 'Lot: 2024')",
          "No testing laboratory identified",
          "HPLC purity listed without a chromatogram",
          "No mass spectrometry data",
          "Analysis date that predates the supplier's business existence",
          "Purity stated as 'tested by manufacturer' with no third-party reference",
          "COA with no analyst name or laboratory signature",
        ],
      },
    ],
    faqs: [
      {
        question: "What does ≥99% purity by HPLC mean?",
        answer:
          "It means that in the HPLC chromatogram, the peak corresponding to the target peptide accounts for at least 99% of the total peak area. The remaining ≤1% may include synthesis byproducts, degradation products, or residual reagents.",
      },
      {
        question: "Is HPLC purity the same as mass spectrometry identity?",
        answer:
          "No — they measure different things. HPLC measures purity (how much of the sample is the target compound vs. impurities). Mass spectrometry confirms molecular identity (that the compound has the correct molecular weight). Both should be present on a complete COA.",
      },
      {
        question: "Should a COA come from a third-party lab?",
        answer:
          "Third-party independent COAs are the gold standard because there is no conflict of interest — the testing laboratory has no financial stake in the result. In-house COAs are less reliable for this reason.",
      },
      {
        question: "How do I match a COA to my specific vial?",
        answer:
          "Check the lot/batch number. The lot number on your COA should exactly match the lot number printed on your vial label. If these don't match, the COA does not apply to your material.",
      },
      {
        question: "What purity should I expect for research-grade peptides?",
        answer:
          "The accepted benchmark for research-grade peptides is ≥99% purity by HPLC. Materials below 98% are generally considered below research grade and may introduce confounding variables into experimental results.",
      },
    ],
    relatedProducts: ["bpc-157", "ghk-cu", "tb-500", "retatrutide"],
    relatedSlugs: [
      "research-grade-peptide-purity-standards",
      "bpc-157-research-overview",
      "ghk-cu-copper-peptide-guide",
    ],
  },

  {
    slug: "tb-500-thymosin-beta-4-research",
    title: "TB-500 (Thymosin Beta-4): Preclinical Research Overview",
    metaTitle: "TB-500 Thymosin Beta-4 Research Overview | Vertex Research Labs",
    metaDescription:
      "Preclinical research overview of TB-500 (Thymosin Beta-4 Acetate). Covers actin-binding properties, cytoskeletal research, published literature, and why it is one of the most studied peptides in preclinical science.",
    keywords: [
      "TB-500 research",
      "Thymosin Beta-4 research",
      "TB-500 preclinical",
      "Thymosin Beta-4 actin binding",
      "TB-500 cytoskeletal research",
      "Tβ4 published studies",
      "TB-500 mechanism",
      "Thymosin Beta-4 cell migration",
    ],
    publishedDate: "2025-02-25",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "TB-500 is the synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding peptide. It has one of the largest published preclinical research bodies of any peptide reference material, with studies appearing in FASEB Journal, Annals of the New York Academy of Sciences, and numerous other journals.",
    sections: [
      {
        heading: "What Is TB-500?",
        content:
          "TB-500 is the synthetic form of the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. Tβ4 is one of the most abundant intracellular peptides in eukaryotic cells and plays a central role in regulating actin polymerization. TB-500 as a research material is typically the 17-amino-acid fragment representing the actin-binding domain, though formulations may vary. Vertex Research Labs supplies TB-500 / Thymosin Beta-4 Acetate as the full-length synthetic equivalent.",
        list: [
          "Natural source: Encoded by the TMSB4X gene on the X chromosome",
          "Length: 43 amino acids (Tβ4 full length) / 17 aa actin-binding fragment",
          "Molecular weight (Tβ4 acetate): ~4963.5 Da",
          "Primary function: Actin monomer (G-actin) sequestration",
          "Intracellular abundance: One of the highest-concentration peptides in mammalian cells",
        ],
      },
      {
        heading: "Actin Biology and the Role of Thymosin Beta-4",
        content:
          "To understand TB-500 research, understanding actin biology is essential. Actin exists in two forms: monomeric G-actin (globular) and filamentous F-actin. The dynamic balance between G-actin and F-actin — controlled by proteins including Thymosin Beta-4 — regulates cell motility, shape, and cytoskeletal structure. Tβ4 acts as a G-actin sequestering protein, binding free actin monomers and modulating when and where new actin filaments can form. This places it at the center of cytoskeletal biology research.",
      },
      {
        heading: "Published Research Highlights",
        content:
          "The Thymosin Beta-4 / TB-500 research literature is extensive. Key published works include foundational studies by Goldstein AL and colleagues in Annals of the New York Academy of Sciences (1997) characterizing the peptide's biological properties, and work by Philp D et al. in FASEB Journal (2011) examining cell migration models. Research by Huff T et al. and others has characterized the structural basis of actin binding at atomic resolution. All cited research is preclinical.",
      },
      {
        heading: "Research Areas Covered in the Literature",
        content:
          "The published TB-500 / Tβ4 literature spans multiple research disciplines, reflecting the peptide's central role in cytoskeletal biology.",
        list: [
          "Actin polymerization dynamics and G-actin sequestration",
          "Cell migration assays (scratch assays, transwell models)",
          "Cardiac fibroblast and cardiomyocyte models",
          "Corneal epithelial cell research",
          "Tendon cell proliferation and migration in vitro",
          "Angiogenesis models (endothelial cell tube formation)",
        ],
      },
      {
        heading: "TB-500 and BPC-157: Frequently Co-Researched",
        content:
          "TB-500 and BPC-157 are among the most frequently co-studied peptides in the preclinical literature. Researchers investigating cytoskeletal dynamics, tissue remodeling models, or growth factor signaling often use both as reference materials in parallel experimental arms. Vertex Research Labs offers both individually and as the Wolverine Blend (BPC-157 5mg + TB-500 5mg) for researchers who need both in a single verified vial.",
      },
      {
        heading: "Disclaimer",
        content:
          "TB-500 / Thymosin Beta-4 Acetate reference materials from Vertex Research Labs are supplied for laboratory research use only. All research cited is preclinical. No claims regarding human therapeutic use are made. This material is not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "Is TB-500 the same as Thymosin Beta-4?",
        answer:
          "TB-500 is the synthetic form associated with the actin-binding active region of Thymosin Beta-4 (Tβ4). The natural peptide is 43 amino acids; TB-500 may refer to the full synthetic equivalent or the active 17-amino-acid fragment depending on the formulation. Vertex Research Labs supplies TB-500 / Thymosin Beta-4 Acetate.",
      },
      {
        question: "What makes TB-500 important in cytoskeletal research?",
        answer:
          "Thymosin Beta-4 is one of the primary G-actin sequestering proteins in eukaryotic cells, placing it at a central regulatory node in cytoskeletal dynamics. This makes it a highly relevant reference tool for any research involving cell motility, migration, or cytoskeletal remodeling.",
      },
      {
        question: "What purity is research-grade TB-500?",
        answer:
          "Vertex Research Labs supplies TB-500 at ≥99% purity by HPLC with a batch-specific Certificate of Analysis. Given its larger molecular weight (~4963 Da), mass spectrometry identity confirmation is standard.",
      },
      {
        question: "Can TB-500 and BPC-157 be ordered together?",
        answer:
          "Yes — they are available individually or as the Wolverine Blend (5mg BPC-157 + 5mg TB-500 in a single co-lyophilized vial) for researchers studying both peptides in the same protocol.",
      },
    ],
    relatedProducts: ["tb-500", "bpc-157", "wolverine-blend"],
    relatedSlugs: [
      "bpc-157-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "glp1-peptides-research-overview",
    title: "GLP-1 Peptides in Research: Semaglutide, Tirzepatide, and Retatrutide",
    metaTitle: "GLP-1 Peptides Research Overview: Semaglutide, Tirzepatide, Retatrutide | Vertex Research Labs",
    metaDescription:
      "Research overview of the GLP-1 peptide class: comparing Semaglutide, Tirzepatide, and Retatrutide as incretin receptor research tools. Covers receptor targets, structural differences, and published clinical data.",
    keywords: [
      "GLP-1 peptide research",
      "Semaglutide research",
      "Tirzepatide research",
      "Retatrutide research",
      "GLP-1 receptor agonist",
      "incretin peptide research",
      "GLP-1 GIP glucagon",
      "GLP-1 peptide comparison",
      "GLP-1 class peptides 2024 2025",
      "trending peptide research",
    ],
    publishedDate: "2025-03-10",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 9,
    excerpt:
      "The GLP-1 peptide class has emerged as one of the most active areas in metabolic research. This overview compares Semaglutide, Tirzepatide, and Retatrutide as distinct research tools — covering their receptor targets, structural properties, and published clinical data.",
    sections: [
      {
        heading: "The Incretin Hormone System",
        content:
          "GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food intake. It stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying in a glucose-dependent manner. GIP (Glucose-dependent Insulinotropic Polypeptide) is a related incretin hormone secreted by intestinal K-cells with complementary effects. Glucagon, secreted by pancreatic alpha-cells, counteracts insulin and promotes glucose production. The GLP-1 class of synthetic peptides mimics and extends the actions of these endogenous hormones, making them central tools in metabolic receptor research.",
      },
      {
        heading: "Semaglutide: GLP-1R Mono-Agonist",
        content:
          "Semaglutide (brand names Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor mono-agonist developed by Novo Nordisk. It consists of a 34-amino-acid sequence homologous to human GLP-1(7-37) with two substitutions and a C18 fatty diacid acylation at Lys26 for albumin binding and extended half-life. FDA-approved for type 2 diabetes management and chronic weight management, it is the reference compound for GLP-1R agonism research. As an approved drug it is not supplied by Vertex Research Labs, but understanding its pharmacology provides essential context for researchers studying the broader GLP-1 class.",
        list: [
          "Receptor: GLP-1R only (mono-agonist)",
          "Half-life: ~1 week (albumin-bound)",
          "Route of administration (clinical): Subcutaneous or oral",
          "Approval status: FDA-approved (multiple indications)",
        ],
      },
      {
        heading: "Tirzepatide: GLP-1R / GIPR Dual Agonist",
        content:
          "Tirzepatide (Mounjaro, Zepbound) is a 39-amino-acid synthetic peptide developed by Eli Lilly that acts as a dual agonist at both GLP-1R and GIPR. Its C20 fatty diacid acylation provides extended half-life similar to Semaglutide. Phase 3 SURMOUNT trials published in NEJM (2022) established its clinical profile. For researchers, Tirzepatide's dual-receptor pharmacology makes it a useful comparator for studying synergistic incretin receptor signaling versus single-receptor activation.",
        list: [
          "Receptors: GLP-1R + GIPR (dual agonist)",
          "Half-life: ~5 days",
          "Approval status: FDA-approved (type 2 diabetes, obesity)",
        ],
      },
      {
        heading: "Retatrutide: GLP-1R / GIPR / GCGR Triple Agonist",
        content:
          "Retatrutide (LY3437943, Eli Lilly) extends the dual-agonism of Tirzepatide by adding full glucagon receptor (GCGR) agonism, creating the first triple-receptor incretin peptide to reach Phase 2 clinical trials. Phase 2 data published in NEJM (Jastreboff AM et al., 2023) reported the metabolic effects of multiple dose levels over 48 weeks. Retatrutide is investigational with no approved indication as of 2025 and is available from Vertex Research Labs as a research reference material.",
        list: [
          "Receptors: GLP-1R + GIPR + GCGR (triple agonist)",
          "Status: Investigational (Phase 2 completed)",
          "Key publication: NEJM 2023; 389:514–526",
        ],
      },
      {
        heading: "Comparative Receptor Profile Summary",
        content:
          "For researchers designing comparative studies of GLP-1 class peptides, this receptor target matrix provides a quick reference.",
        list: [
          "Semaglutide: GLP-1R ✓ | GIPR ✗ | GCGR ✗",
          "Tirzepatide: GLP-1R ✓ | GIPR ✓ | GCGR ✗",
          "Retatrutide: GLP-1R ✓ | GIPR ✓ | GCGR ✓",
        ],
      },
      {
        heading: "Research Applications",
        content:
          "For laboratory researchers, these peptides offer distinct tools for probing incretin biology. Retatrutide is the only one of the three available as a research reference material from Vertex Research Labs, as Semaglutide and Tirzepatide are FDA-approved drugs subject to different regulatory frameworks.",
      },
      {
        heading: "Disclaimer",
        content:
          "This overview is for scientific reference only. No therapeutic claims are made for any compound discussed. Semaglutide and Tirzepatide are FDA-approved drugs not supplied by Vertex Research Labs. Retatrutide is supplied as a laboratory research reference material only and is not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "What does GLP-1 stand for?",
        answer:
          "GLP-1 stands for Glucagon-Like Peptide-1. It is an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient intake, involved in glucose-dependent insulin secretion.",
      },
      {
        question: "What makes Retatrutide different from Tirzepatide?",
        answer:
          "Tirzepatide is a dual GLP-1R/GIPR agonist. Retatrutide adds full GCGR (glucagon receptor) agonism to that profile, creating a triple-receptor pharmacology. This additional receptor activity is the primary research interest distinguishing Retatrutide.",
      },
      {
        question: "Can I buy Semaglutide or Tirzepatide as a research peptide?",
        answer:
          "Semaglutide and Tirzepatide are FDA-approved drugs and are not supplied by Vertex Research Labs. Retatrutide remains investigational and is available as a research reference material.",
      },
      {
        question: "Where is the Retatrutide Phase 2 data published?",
        answer:
          "The Phase 2 trial data was published in the New England Journal of Medicine: Jastreboff AM et al., NEJM 2023; 389:514–526. DOI: 10.1056/NEJMoa2301972.",
      },
    ],
    relatedProducts: ["retatrutide", "tesamorelin", "cjc-ipa-blend"],
    relatedSlugs: [
      "retatrutide-triple-agonist-research",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "research-grade-peptide-purity-standards",
    title: "Research Grade Peptides: What Purity Standards Actually Mean",
    metaTitle: "Research Grade Peptide Purity Standards Explained | Vertex Research Labs",
    metaDescription:
      "What does '≥99% purity' actually mean for research peptides? A clear explanation of HPLC purity grading, why it matters for reproducible research, and how to evaluate supplier quality claims.",
    keywords: [
      "research grade peptide purity",
      "peptide purity standards",
      "99% purity peptide meaning",
      "HPLC peptide grade",
      "research peptide quality",
      "how pure should research peptides be",
      "peptide purity vs research grade",
      "best purity peptides for research",
      "peptide supplier quality",
    ],
    publishedDate: "2025-03-15",
    modifiedDate: "2025-04-01",
    category: "Research Guide",
    readTime: 6,
    excerpt:
      "The phrase 'research grade' is used widely in the peptide industry, but what does it actually mean? This guide demystifies purity grades, explains what HPLC purity numbers represent, and explains why purity matters for experimental reproducibility.",
    sections: [
      {
        heading: "What Does 'Research Grade' Mean?",
        content:
          "Unlike pharmaceutical grade (which is governed by official pharmacopoeias such as USP or BP), 'research grade' is not a formally regulated term. In practice, however, the scientific community has converged on clear standards. Research-grade peptides are expected to meet ≥99% purity by HPLC, with confirmed molecular identity by mass spectrometry and full batch documentation. Materials below this threshold are generally considered substandard for use in peer-reviewed research where data reproducibility is required.",
      },
      {
        heading: "Purity Grades Explained",
        content:
          "Peptide suppliers typically offer materials across several purity tiers. Understanding these helps researchers select the right material for their protocol.",
        list: [
          "≥95% purity: Minimum acceptable for exploratory screening; not suitable for publications",
          "≥98% purity: Acceptable for some research applications; still carries meaningful impurity load",
          "≥99% purity: The accepted research-grade standard; suitable for most published research protocols",
          "≥99.5% purity: High-purity grade; preferred for sensitive assays or reference standard use",
          "Pharmaceutical grade (USP/BP): Governed by official pharmacopoeias; not the same as research grade",
        ],
      },
      {
        heading: "Why Purity Matters for Research Reproducibility",
        content:
          "In a biological assay, a peptide at 95% purity contains 5% unknowns — synthesis byproducts, truncated sequences, oxidized variants, or residual reagents. In a cell culture experiment, these impurities can interact with receptors, enzymes, or signaling pathways, producing results that have nothing to do with the target peptide. This is a significant source of irreproducibility in peptide research. Using ≥99% purity material with confirmed identity eliminates the vast majority of this confounding factor.",
      },
      {
        heading: "Common Impurities in Synthetic Peptides",
        content:
          "Solid-phase peptide synthesis (SPPS), the standard method for producing research peptides, generates characteristic impurity profiles that a high-quality HPLC analysis should resolve.",
        list: [
          "Deletion sequences (peptides missing one or more amino acids from incomplete coupling)",
          "Truncated sequences (incomplete peptide chains from early termination)",
          "Oxidized variants (methionine, cysteine, or tryptophan oxidation)",
          "Racemized residues (D-amino acid incorporation during synthesis)",
          "Residual protecting groups from SPPS chemistry",
          "TFA salt (trifluoroacetate counter-ion from purification; can affect some biological assays)",
        ],
      },
      {
        heading: "How to Verify Purity Claims",
        content:
          "A supplier claiming ≥99% purity should be able to support that claim with documentation. The minimum acceptable evidence is a batch-specific HPLC chromatogram (not just a percentage number) from an independent laboratory, accompanied by mass spectrometry identity confirmation. Without these two pieces of evidence, a purity claim cannot be independently verified.",
      },
      {
        heading: "Vertex Research Labs Quality Standard",
        content:
          "Every peptide supplied by Vertex Research Labs meets the ≥99% purity standard as verified by independent third-party HPLC analysis. Each batch ships with a Certificate of Analysis documenting the HPLC chromatogram, mass spectrometry identity confirmation, lot number, testing laboratory, and analysis date. We do not sell peptides without independent COA documentation.",
      },
    ],
    faqs: [
      {
        question: "Is ≥99% purity enough for published research?",
        answer:
          "Yes — ≥99% purity by HPLC is the accepted standard for most peer-reviewed research protocols. For highly sensitive assays or reference standard applications, ≥99.5% may be preferred.",
      },
      {
        question: "What is TFA salt and does it matter?",
        answer:
          "TFA (trifluoroacetic acid) is used in peptide purification and leaves a trifluoroacetate counter-ion on the final peptide salt. In most biological assays this is inconsequential, but TFA can be cytotoxic at higher concentrations. For sensitive cell culture assays at high peptide concentrations, acetate salt form peptides are preferable.",
      },
      {
        question: "Can I use 95% purity peptides for research?",
        answer:
          "Technically yes, but the 5% impurity load introduces meaningful risk of confounding results, especially in receptor binding assays or cell-based studies. For any research intended for publication, ≥99% purity is the recommended minimum.",
      },
      {
        question: "How do I know if a supplier's purity claim is real?",
        answer:
          "Request a batch-specific COA showing the HPLC chromatogram (not just the percentage number), the testing laboratory's name, and mass spectrometry data. If a supplier cannot provide these, their purity claim cannot be independently verified.",
      },
    ],
    relatedProducts: ["bpc-157", "ghk-cu", "tb-500", "retatrutide"],
    relatedSlugs: [
      "how-to-read-peptide-coa",
      "bpc-157-research-overview",
      "ghk-cu-copper-peptide-guide",
    ],
  },

  {
    slug: "cjc-1295-ipamorelin-research",
    title: "CJC-1295 and Ipamorelin: GH-Axis Research Tools Explained",
    metaTitle: "CJC-1295 and Ipamorelin Research Overview: GHRH + GHS | Vertex Research Labs",
    metaDescription:
      "Research overview of CJC-1295 (No DAC) and Ipamorelin as complementary GH-axis research tools. Covers GHRH receptor vs GHS-R1a pharmacology, published studies, and why researchers use them together.",
    keywords: [
      "CJC-1295 research",
      "Ipamorelin research",
      "CJC-1295 Ipamorelin",
      "GHRH analog research",
      "GH secretagogue research",
      "GHS-R1a agonist",
      "CJC-1295 No DAC",
      "growth hormone research peptide",
      "CJC Ipamorelin blend research",
      "GH axis peptide research",
    ],
    publishedDate: "2025-03-20",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "CJC-1295 (No DAC) and Ipamorelin represent two complementary entry points into GH-axis research — one targeting GHRH receptors, the other targeting GHS-R1a. Together they allow researchers to study synergistic GH secretagogue pathways using distinct but compatible receptor tools.",
    sections: [
      {
        heading: "The GH Axis: Two Research-Relevant Pathways",
        content:
          "Growth hormone (GH) secretion from the anterior pituitary is regulated by two primary hypothalamic inputs: GHRH (Growth Hormone-Releasing Hormone), which stimulates GH release via GHRHR, and Somatostatin, which inhibits GH release. A third pathway involves Ghrelin, which stimulates GH via the GHS-R1a receptor. CJC-1295 acts on the GHRH receptor pathway; Ipamorelin acts on the GHS-R1a/ghrelin receptor pathway. This complementary receptor biology is the primary reason they are studied together.",
      },
      {
        heading: "CJC-1295 (No DAC): A GHRH Analog",
        content:
          "CJC-1295 is a synthetic analog of GHRH, modified from the native 44-amino-acid sequence. The 'No DAC' designation refers to the absence of the Drug Affinity Complex — a reactive MPA (maleimidoproprionic acid) group that, in the DAC version, covalently binds to albumin for extended half-life. The No DAC variant has a shorter half-life more suitable for pulsatile GH secretion research protocols. Published pharmacokinetic data appeared in Journal of Clinical Endocrinology & Metabolism (Teichman SL et al., 2006).",
        list: [
          "Target receptor: GHRHR (Growth Hormone-Releasing Hormone Receptor)",
          "Mechanism: GHRH receptor agonist",
          "Key distinction: No DAC = shorter half-life, pulse-friendly",
          "Published in: J Clin Endocrinol Metab 2006; 91:799–805",
        ],
      },
      {
        heading: "Ipamorelin: A Selective GH Secretagogue",
        content:
          "Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist at the GHS-R1a receptor — the ghrelin receptor. Research by Raun K et al. published in European Journal of Endocrinology (1998) characterized Ipamorelin as highly selective for GH release, with minimal stimulation of other pituitary hormones (ACTH, cortisol, prolactin) compared to earlier GH secretagogues like GHRP-6. This selectivity makes it a cleaner research tool for GH-axis studies.",
        list: [
          "Target receptor: GHS-R1a (Ghrelin receptor)",
          "Mechanism: Selective GH secretagogue",
          "Key selectivity: Minimal ACTH/cortisol stimulation vs GHRP-6",
          "Published in: Eur J Endocrinol 1998; 139:552–561",
        ],
      },
      {
        heading: "Why Researchers Use CJC-1295 and Ipamorelin Together",
        content:
          "CJC-1295 and Ipamorelin target distinct but synergistic receptor pathways — GHRHR and GHS-R1a respectively. In preclinical models, co-administration of GHRH analogs and GH secretagogues has demonstrated additive GH secretion effects, as the two pathways converge on different intracellular signaling cascades (cAMP for GHRHR; IP3/PKC for GHS-R1a) within the same somatotroph cell. For researchers studying GH secretion dynamics, this makes the combination particularly informative.",
      },
      {
        heading: "The CJC/IPA Blend from Vertex Research Labs",
        content:
          "Vertex Research Labs offers a pre-blended CJC/IPA Blend containing CJC-1295 (No DAC) 5mg and Ipamorelin 5mg in a single 10mg research vial. Both components are independently verified at ≥99% purity with a combined batch-specific COA. This format is designed for researchers who need both peptides simultaneously without managing two separate procurement and reconstitution workflows.",
      },
      {
        heading: "Disclaimer",
        content:
          "CJC-1295 and Ipamorelin reference materials from Vertex Research Labs are supplied for laboratory research use only. Neither compound is FDA-approved. Published research cited is preclinical or early-phase clinical only. No health or therapeutic claims are made. Not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between CJC-1295 with DAC and without DAC?",
        answer:
          "CJC-1295 with DAC contains a Drug Affinity Complex that covalently binds albumin, extending half-life to approximately 8 days. Without DAC, the half-life is approximately 30 minutes, similar to native GHRH. The No DAC form is preferred for research protocols studying pulsatile GH dynamics.",
      },
      {
        question: "Why is Ipamorelin considered more selective than other GH secretagogues?",
        answer:
          "Ipamorelin was characterized in a 1998 European Journal of Endocrinology study as stimulating GH release with minimal stimulation of ACTH, cortisol, or prolactin — a cleaner profile than earlier secretagogues like GHRP-2 or GHRP-6, which significantly stimulate corticotropin release.",
      },
      {
        question: "Are CJC-1295 and Ipamorelin available separately?",
        answer:
          "Yes — both are available individually. The CJC/IPA Blend (10mg, 1:1 ratio) is offered for researchers who need both in a single verified reference vial.",
      },
      {
        question: "What purity is the CJC/IPA Blend?",
        answer:
          "Both CJC-1295 and Ipamorelin in the blend are independently verified at ≥99% purity. The blend ships with a Certificate of Analysis covering both components.",
      },
    ],
    relatedProducts: ["cjc-ipa-blend", "tesamorelin", "mots-c"],
    relatedSlugs: [
      "retatrutide-triple-agonist-research",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },
];
